New data from the KEYNOTE-756 trial show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status (IMAGE)

European Organisation for Research and Treatment of Cancer

New data from the KEYNOTE-756 trial show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status

Caption

Prof. Javier Cortes

Credit

Prof. Javier Cortes

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.